Although the IgG isotype represents the majority of mAbs approved for cancer immunotherapy and their activity is usually also associated with activation of the CS, the IgM isotype may be a better alternative due to its higher avidity for the target and because it is the most efficient CS activator [9, 10]. This evidence concerns the gene CD40LG and cancer.